1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Clear Path For AstraZeneca’s Roxadustat After Reassuring Safety Data

Filing Expected Before Year-End

 
• By Andrew McConaghie

Strong results in non-dialysis patients are a particular boost for AZ and its partner, Fibrogen.

AZ_China
AstraZeneca's operations in China, where roxodustat is already approved • Source: AstraZeneca

AstraZeneca PLC and FibroGen Inc. will be confident of US approval for roxadustat after unveiling reassuring cardiovascular safety data for their new anemia treatment.

Roxadustat is the front runner in a new class of oral HIF-PH inhibitors used to treat anemia, and needed to show superiority in safety compared to existing standard treatment,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.